- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acoustic Imaging is alive and well
Ultrasound vendor Acoustic Imagingis still open for business, contrary to a rumor that swept throughthe industry late last month hinting that the Phoenix-based companyhad closed its doors. The firm enjoyed a strong September andis looking forward to the
Ultrasound vendor Acoustic Imagingis still open for business, contrary to a rumor that swept throughthe industry late last month hinting that the Phoenix-based companyhad closed its doors. The firm enjoyed a strong September andis looking forward to the Radiological Society of North Americameeting this month, according to president John Kingsley.
The last several years have been bumpy for AI. The companyhas frequently been the target of rumors that its parent, DornierMedical Systems, is close to selling off the firm. Dornier boughta controlling interest in AI in 1989 (SCAN 9/27/89).
Kingsley came on board in 1993 in a restructuring that sawthe firm trim its payroll and focus on cost-effective systemslike its Performa scanner, released last year (SCAN 2/24/93 and12/29/93). Those efforts have paid off, and this year AcousticImaging's sales are progressing well and the company is aheadof its business plan, Kingsley said.
"We had the best month (in September) since I've beenon board," Kingsley said. "I don't see (the rumor's)foundation in fact, unless we're making a few people nervous."
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
